HealthEquity stock’s recent year-to-date underperformance is partly due to its disclosure of fraud against some of its HSA customers and near-term investor concerns about recent management changes.

marks a new chapter for HealthEquity. Investors and analysts will be closely watching how this leadership transition influences the company’s strategic direction and execution of its growth plans. The ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $112.5, ...

On this news, HealthEquity shares fell 17% on March 19, 2025.

Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether HealthEquity and certain of its officers and/or ...

11 New Issues of Our Premium Readership Newsletter ... HQY) in its Q4 2024 investor letter: “HealthEquity, Inc. (NASDAQ:HQY) was another top contributor. HealthEquity is the largest U.S ...

In response to these issues, management has adjusted its ... marks a new chapter for HealthEquity. Investors and analysts will be closely watching how this leadership transition influences the ...

Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether HealthEquity and certain of its officers and/or ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of HealthEquity, Inc. (NASDAQ ...